AZN vs EXEL
AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline. EXEL: Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline of next-generation small molecules and antibody-drug conjugates.
Side-by-side fundamentals
| Metric | AZN | EXEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $169.73 | $54.98 | |
| Market cap as of 2026-07-23 | $193.7B | $14.0B | |
| P/E as of 2026-07-23 | 24.93 | 16.74 | EXEL lower |
| PEG as of 2026-07-23 | 2.64 | 1.09 | EXEL lower |
| Net margin as of 2026-07-23 | +17.2% | +35.1% | EXEL higher |
| Gross margin as of 2026-07-23 | +81.4% | +96.4% | EXEL higher |
| Operating margin as of 2026-07-23 | +23.7% | +39.4% | EXEL higher |
| ROE as of 2026-07-23 | +22.3% | +40.2% | EXEL higher |
| ROA as of 2026-07-23 | +9.1% | +30.5% | EXEL higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | EXEL lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | +7.9% | AZN higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.5% | |
| Dividend yield as of 2026-07-23 | +1.9% | n/a | |
| Beta as of 2026-07-23 | 1.38 | 0.41 | |
| 1-year return as of 2026-07-22 close | +17.0% | +26.8% | EXEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.